Research Report Covers the Global Diabetic Neuropathy Market 2023

Diabetic Neuropathy Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of Diabetic Neuropathy Market by disorder type(distribution channel), by treatment type(drugs, radiotherapy and physiotherapy), by distribution channel(hospitals, clinics, retails pharmacy and online pharmacy) market status and outlook of global and major regions, from manufacturers, and end industries. As this report is expected to help key players among the Diabetic Neuropathy Market it includes the five years Industry analysis and the 6 years annual forecast from 2017 to 2023. Some of the prominent participants in the Global Diabetic Neuropathy Market are Janssen Pharmaceuticals, Inc, Eli Lilly and Company, ACTAVIS, Cephalon Inc, MEDA Pharma GmBH & Co. KG, GlaxoSmithKline, NeuroMetrix, Inc, and Johnson and Johnson. According to the report the Global Diabetic Neuropathy Market is projected to grow at a CAGR between 5.0 % to 5.5 % in terms of value over the period of 2017-2023.

Increasing Diabetes Cases Worldwide, Rapid Product Launches and Increasing Mergers and Acquisition, Global Diabetic Neuropathy Market will have Massive Growth Opportunities

Growing awareness among people is considered as major market driver for diabetic neuropathy market. Moreover, global market is primarily driven by changing lifestyle which has mostly resulted into unhealthy dietary habits and patterns. In addition, factors such as increasing aging population, rise in healthcare expenditure for diabetes, growing awareness about diabetes, and rise in R&D activities in drug discovery and development have contributed in the global growth. However, growth of this market is predominantly restrained by longer approval time for drugs and side effects and rising cost of diabetic neuropathy treatment. Also, stringent regulatory requirement and significant failure rate during the clinical trials expected to be the growth barriers in the years to come.On account of increasing diabetes cases worldwide, rapid product launches and increasing mergers and acquisition, global diabetic neuropathy market will have massive growth opportunities. Rising cost of diabetic neuropathy treatment expected to remain as challenge in front of this market throughout the forecast period.

North America is the Largest Market for Diabetic Neuropathy Globally, with Over 35% of Global Market Shares Followed by Europe

The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section the key trends and market size for each geography is provided over the period of 2017 – 2023.North America is the largest market for diabetic neuropathy globally, with over 35% of global market shares followed by Europe. Growth in this region is attributed to increasing numbers of diabetic cases linked with rising awareness among people about diabetes and related complication, and significant rise in research and development activities. Increasing diabetes rate in this region has surged growth for diabetic neuropathy in North America region. Furthermore, US and Canada are the major markets in this region and has played major role in the regional growth. Following North America, Europe is the second largest market for diabetic neuropathy. Asia Pacific, however, is the emerging market anticipated to grow at highest growth rate over the forecast period. This is due to increasing government support in the form of funding, developing healthcare infrastructure across the region and economic development in this region. Moreover, India is one of the dynamic markets in APAC region projected to contribute significantly in regional growth.

Major Key Players Covered in this Premium Report:

The companies covered in the report include Pfizer Inc, Janssen Pharmaceuticals, Inc, Eli Lilly and Company, ACTAVIS, CephalonInc, MEDA PharmaGmBH& Co. KG, GlaxoSmithKline, NeuroMetrix, Inc, and Johnson and Johnson.

Segments Covered:

The report segments the global diabetic neuropathy market by disorder type, by treatment type, by distribution channel by region. The market size of each segment has been provided in terms of value (USD). Based on disorder type, global market has been divided into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Market segmentation based on the treatment type includes drugs, Radiotherapy, and physiotherapy. Moreover, Drugs further sub-segmented into analgesic, antidepressant, and anticonvulsants. Moreover, on the basis of distribution channel market segmented into hospitals, clinics, retails pharmacy, and online pharmacy.

Table of Contents:-

1. Preface

1.1 Report Description

1.2 Research Methods

1.3 Research Approaches

2. Executive Summary

3. Global Diabetic Neuropathy Market Overview

3.1 Introduction

3.2 Market Dynamics

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunities

3.3 Porter’s Five Forces Analysis

3.4 IGR – Growth Matrix Analysis

3.5 Competitive Landscape in the Diabetic Neuropathy Market

4. Global Diabetic Neuropathy Market : IGR Snapshots

4.1 Global Diabetic Neuropathy Market key Trends

4.2 Global Diabetic Neuropathy Market by Application

4.3 Global Diabetic Neuropathy Market by Region

5. Global Diabetic Neuropathy by Disorder Type (USD Billion) 2017 – 2023

5.1 Peripheral Neuropathy

5.2 Autonomic Neuropathy

5.3 Proximal Neuropathy

5.4 Focal Neuropathy

6. Global Diabetic Neuropathy Market Analysis, by Treatment Type(USD Billion) 2017 – 2023

6.1 Drugs

6.1.1 Analgesics

6.1.1.1 Topical

6.1.1.2 Opioids

6.1.1.3 NSAIDs

6.1.2 Antidepressant

6.1.2.1 TCAs

6.1.2.2 SNRIs

6.1.2.3 SSRIs

6.1.3 Anticonvulsants

6.1.3.1 Pregabalin

6.1.3.2 Topimarate

6.1.3.3 Gabapentin

6.1.3.4 Others

6.2 Radiotherapy

6.2.1 TENS

6.2.2 Other

6.3 Physiotherapy

7. Global Diabetic Neuropathy Market Analysis, by Distribution channel (USD Billion) 2017 – 2023

7.1 Hospitals

7.2 Clinics

7.3 Retail Pharmacy

7.4 Online Pharmacy

8. Global Diabetic Neuropathy Market Analysis, by Region (USD Billion) 2017 – 2023

8.1 North America

8.1.1 North America Diabetic Neuropathy Market by Disorder Type (USD Billion

8.1.2 North America Diabetic Neuropathy Market by Treatment Type (USD Billion)

8.1.3 North America Diabetic Neuropathy Market by Distribution Channel (USD Billion)

8.2 Europe

8.1.1 Europe Diabetic Neuropathy Market by Disorder Type (USD Billion)

8.1.2 Europe Diabetic Neuropathy Market by Treatment Type (USD Billion)

8.1.3 Europe Diabetic Neuropathy Market by Distribution Channel (USD Billion)

8.3 Asia Pacific

8.1.1 Asia Pacific Diabetic Neuropathy Market by Disorder Type (USD Billion)

8.1.2 Asia Pacific Diabetic Neuropathy Market by Treatment Type (USD Billion)

8.1.3 Asia Pacific Diabetic Neuropathy Market by Distribution Channel (USD Billion)

8.4 RoW

8.1.1 RoW Diabetic Neuropathy Market by Disorder Type (USD Billion

8.1.2 RoW Diabetic Neuropathy Market by Treatment Type (USD Billion)

8.1.3 RoW Diabetic Neuropathy Market by Distribution Channel (USD Billion)

9. Company Profiles

9.1 Pfizer Inc

9.2 Janssen Pharmaceuticals, Inc

9.3 Eli Lilly and Company

9.4 ACTAVIS

9.5 CephalonInc

9.6 MEDA Pharma GmBH& Co. KG

9.7 GlaxoSmithKline

9.8 NeuroMetrix

9.9 Johnson and Johnson

9.10 Others

Click the Below Full Report:-

https://www.infiniumglobalresearch.com/healthcare_medical_devices/global_diabetic_neuropathy_market



Reset Password